EP0583360A4 - - Google Patents

Info

Publication number
EP0583360A4
EP0583360A4 EP19920911373 EP92911373A EP0583360A4 EP 0583360 A4 EP0583360 A4 EP 0583360A4 EP 19920911373 EP19920911373 EP 19920911373 EP 92911373 A EP92911373 A EP 92911373A EP 0583360 A4 EP0583360 A4 EP 0583360A4
Authority
EP
European Patent Office
Prior art keywords
lmwh
present
tnf
alpha secretion
decm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19920911373
Other languages
English (en)
Other versions
EP0583360A1 (de
EP0583360B1 (de
Inventor
Irun R Cohen
Ofer Lider
Rami Herskovitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL9802891A external-priority patent/IL98028A/en
Priority claimed from IL98298A external-priority patent/IL98298A0/xx
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of EP0583360A1 publication Critical patent/EP0583360A1/de
Publication of EP0583360A4 publication Critical patent/EP0583360A4/xx
Application granted granted Critical
Publication of EP0583360B1 publication Critical patent/EP0583360B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Surface Heating Bodies (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP92911373A 1991-05-02 1992-05-01 Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen Expired - Lifetime EP0583360B1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL9802891A IL98028A (en) 1991-05-02 1991-05-02 Pharmaceuticals containing low molecular weight heparin (HWML)
IL98028 1991-05-02
IL98298 1991-05-28
IL98298A IL98298A0 (en) 1991-05-28 1991-05-28 Pharmaceutical compositions comprising a heparin derivative
PCT/US1992/003626 WO1992019249A1 (en) 1991-05-02 1992-05-01 Compositions for the prevention and/or treatment of pathological processes

Publications (3)

Publication Number Publication Date
EP0583360A1 EP0583360A1 (de) 1994-02-23
EP0583360A4 true EP0583360A4 (de) 1994-04-06
EP0583360B1 EP0583360B1 (de) 2002-05-22

Family

ID=26322260

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92911373A Expired - Lifetime EP0583360B1 (de) 1991-05-02 1992-05-01 Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen

Country Status (15)

Country Link
US (3) US5474987A (de)
EP (1) EP0583360B1 (de)
JP (1) JPH06507635A (de)
KR (1) KR100235782B1 (de)
AT (1) ATE217796T1 (de)
AU (1) AU668865B2 (de)
BR (1) BR9205961A (de)
CA (1) CA2102207A1 (de)
CZ (1) CZ232593A3 (de)
DE (1) DE69232615T2 (de)
FI (1) FI934849A (de)
HU (1) HUT67136A (de)
NO (1) NO933942L (de)
SK (1) SK120193A3 (de)
WO (1) WO1992019249A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US6750207B1 (en) * 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
CA2149116A1 (en) * 1992-11-10 1994-05-26 Irun R. Cohen Compositions for the regulation of cytokine activity
AU6204594A (en) * 1993-02-22 1994-09-14 Ulrich-Christoph Von Arnim Use of heparins for the treatment of inflammatory or immunological diseases
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
PT946185E (pt) * 1996-11-27 2005-02-28 Aventis Pharm Prod Inc Composicao farmaceutica compreendendo um composto que possui actividade anti-xa e um composto antagonista da agregacao plaquetaria
DE69835016T2 (de) * 1997-07-14 2007-06-28 Muramatsu, Takashi, Nagoya Verwendung von midkin oder von anti-midkin antikörper
WO2000012726A2 (en) 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
CA2370539C (en) * 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
HUP0201712A3 (en) * 1999-06-30 2003-03-28 Weitz Jeffrey I Ancaster Clot associated coagulation factors inhibiting heparin compositions
AU4351201A (en) 2000-03-08 2001-09-17 Massachusetts Inst Technology Heparinase iii and uses thereof
IL154771A0 (en) * 2000-09-08 2003-10-31 Hamilton Civic Hospitals Res Antithrombotic compositions
EP1319183B1 (de) 2000-09-12 2009-03-25 Massachusetts Institute Of Technology Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
WO2002047696A1 (de) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
US20050123593A1 (en) * 2001-06-25 2005-06-09 Jonathan Thompson Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
AU2002322862A1 (en) * 2001-07-31 2003-02-17 Reddy Us Therapeutics, Inc. Methods and compositions for diagnosis and treatment of vascular conditions
CA2455038A1 (en) * 2001-07-31 2003-02-13 Board Of Regents, University Of Texas System Antigens of and antibodies to translocated molecules of microorganisms and uses thereof
US7285536B2 (en) * 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
EP1542704A1 (de) * 2002-04-18 2005-06-22 Stephen H. Embury VERFAHREN UND ZUSAMMENSETZUNG ZUR PRûVENTION VON SCHMERZEN BEI SICHELZELL-PATIENTEN
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1592373B1 (de) * 2003-01-30 2013-04-24 ProChon Biotech Ltd. Gefriergetrocknete fibrinmatrizen und herstellungsverfahren dafür
WO2005054493A2 (en) * 2003-06-12 2005-06-16 Mayo Foundation For Medical Education And Research Altered activity of toll-like receptors
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
EP2336298B1 (de) 2003-06-27 2016-02-17 DePuy Synthes Products, Inc. Aus der Plazenta postpartum abgeleitete Zellen und deren Herstellungsmethoden und Verwendung
US20060223177A1 (en) 2003-06-27 2006-10-05 Ethicon Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US7560444B2 (en) * 2003-10-01 2009-07-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
EP1731131A1 (de) * 2004-03-29 2006-12-13 Kringle Pharma Inc. Hgf-produktionsbeschleuniger mit heparinähnlichem oligosaccharid
WO2006023487A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Rapid two-step synthesis of anti-coagulants
JP2009507209A (ja) * 2005-07-22 2009-02-19 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア ヘパリン組成物およびセレクチン阻害
AU2006292224B2 (en) 2005-09-19 2013-08-01 Histogenics Corporation Cell-support matrix and a method for preparation thereof
EP2283045A1 (de) * 2008-05-20 2011-02-16 Crystal Clear Partnership Trennung von polysacchariden mittels ladungsdichtegradient
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001501A1 (en) * 1988-08-02 1990-02-22 Linhardt Robert J Oligosaccharide heparin fragments as inhibitors of complement cascade
WO1990003791A1 (en) * 1988-10-05 1990-04-19 Nicola Diferrante Methods for interfering with hiv multiplication and composition for the treatment of aids
EP0375976A2 (de) * 1988-12-01 1990-07-04 Hadassa Medical Organization Verbindungen mit Affinität zu einem Heparinrezeptor als Inhibitoren von T-Zellen-vermittelten Immunreaktionen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4281108A (en) * 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
EP0114589B1 (de) * 1982-12-20 1987-09-23 The President And Fellows Of Harvard College Hemmung der Gefässneubildung
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
US4889808A (en) * 1985-10-01 1989-12-26 American Home Products Method of enchancing t-PA and SCU-PA production
EP0240098A3 (de) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren
US4788307A (en) * 1986-04-30 1988-11-29 Choay S.A. Oligosaccharidic fractions devoid or practically devoid of antithrombotic activity
ES2059321T3 (es) * 1986-05-16 1994-11-16 Italfarmaco Spa Heparinas, fracciones y fragmentos de heparinas libres de edta, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
WO1988000017A1 (en) * 1986-06-27 1988-01-14 Boon Corporation Pty. Ltd. Mat
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
PT93847A (pt) * 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
AT500533B8 (de) * 2000-04-13 2007-02-15 Man Nutzfahrzeuge Ag Gas- oder trolleybus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001501A1 (en) * 1988-08-02 1990-02-22 Linhardt Robert J Oligosaccharide heparin fragments as inhibitors of complement cascade
WO1990003791A1 (en) * 1988-10-05 1990-04-19 Nicola Diferrante Methods for interfering with hiv multiplication and composition for the treatment of aids
EP0375976A2 (de) * 1988-12-01 1990-07-04 Hadassa Medical Organization Verbindungen mit Affinität zu einem Heparinrezeptor als Inhibitoren von T-Zellen-vermittelten Immunreaktionen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EKRE, H.P. ET AL: "ANTI-INFLAMMATORY EFFECTS OF HEPARIN AND ITS DERIVATIVES INHIBITION OF COMPLEMENT AND OF LYMPHOCYTE MIGRATION", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 313, 1992, pages 329 - 340 *
LIDER, O. ET AL: "SUPPRESSION OF AUTOIMMUNE DISEASES AND PROLONGATION OF ALLOGRAFT SURVIVAL BY TREATMENT OF ANIMALS WITH LOW DOSES OF HEPARINS", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 83, no. 3, March 1989 (1989-03-01), pages 752 - 756 *

Also Published As

Publication number Publication date
CA2102207A1 (en) 1992-11-03
EP0583360A1 (de) 1994-02-23
BR9205961A (pt) 1994-07-26
US5908837A (en) 1999-06-01
DE69232615D1 (de) 2002-06-27
EP0583360B1 (de) 2002-05-22
HU9303110D0 (en) 1994-01-28
KR100235782B1 (ko) 1999-12-15
ATE217796T1 (de) 2002-06-15
FI934849A0 (fi) 1993-11-02
AU1913192A (en) 1992-12-21
WO1992019249A1 (en) 1992-11-12
DE69232615T2 (de) 2003-01-30
HUT67136A (en) 1995-02-28
CZ232593A3 (en) 1994-07-13
SK120193A3 (en) 1994-07-06
AU668865B2 (en) 1996-05-23
NO933942L (no) 1993-12-14
FI934849A (fi) 1993-12-31
US5474987A (en) 1995-12-12
NO933942D0 (no) 1993-11-01
JPH06507635A (ja) 1994-09-01
US5686431A (en) 1997-11-11

Similar Documents

Publication Publication Date Title
EP0583360A4 (de)
GB9606736D0 (en) Therapeutic method
EP0675899A4 (de) NEUE INHIBITOREN VON FAKTOR Xa.
MY101207A (en) Treatment of diseases caused by retroviruses
UA43391C2 (uk) Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію
PT921787E (pt) Regime de administracao de inibidores de atpase de h',k'
UA19782A (uk) Спосіб одержаhhя біциклічhих складhих ефірів або їх фармацевтичhо прийhятhих солей
HK1030604A1 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
TJ252B (en) Benzothiophene benzofuran indolethiazepinone oxazepinone and diazepinone derivatives pharmaceutical composition having activity which is inhibited the cellular adhesion or hiv method of inhibition of the adhesion leukocytes to endothelial cells at treatment of the illnesses caused by it method of treatment of the mammalian infected hiv
MD2196B2 (ro) Criptoficine, procedeu de obţinere, compoziţii farmaceutice pe baza acestora, metodă de inhibare a proliferării celulelor mamiferelor şi metodă de atenuare a stării patologice cauzate de hiperproliferarea celulelor mamiferelor
HK1031099A1 (en) Cd8 as an inhibitor of the cellular immune system
EE9900044A (et) Farmatseutilised tooted veresoonte endoteelirakkude kahjustuste tagajärjel tekkinud haiguste raviks ja vältimiseks
MX9806229A (es) Derivados de benzo(c)quinolicina, su preparacion y uso como inhibidores de la 5alfa-reductasas.
ES8706370A1 (es) Procedimiento para prolongar la vida en almacenamiento de plantas de guayule
EP0684831A4 (de) Allogenes vakzin und synthesemethode für selbiges.
RU93058322A (ru) Композиции для предотвращения и/или лечения патологических процессов, способ применения низкомолекулярного гепарина, способ лечения
HU9401977D0 (en) Process for producing pharmaceutical compositions containing beta-naphtoquinone derivatives and salts thereof with epithalial proliferation fastening and no-synthetase inhibiting activity
Cohen et al. Methods of using low molecular weight heparins treatment of pathological processes
ES476703A1 (es) Procedimiento para preparar una heterovacuna para el trata -miento terapeutico del sindrome de los triconomas.
WO1995024907A3 (en) Pharmaceutical compositions containing laminarin sulfate
Morales et al. Experimental immunotherapy with NK-like cells: A preliminary report
SE8306792D0 (sv) Neues terapeutisches preparat enthaltend hydrierte ergotalkaloide und heparin
UA28523A (uk) Спосіб пригнічення репродукції вірусу імунодефіциту людини
RU97117918A (ru) Способ адаптивной иммунотерапии злокачественных новообразований
MY114610A (en) Controlled drug delivery system for diltiazem.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940215

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19970806

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HERSKOVITZ, RAMI

Inventor name: LIDER, OFER

Inventor name: COHEN, IRUN R

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/715 A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020522

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20020522

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020522

REF Corresponds to:

Ref document number: 217796

Country of ref document: AT

Date of ref document: 20020615

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69232615

Country of ref document: DE

Date of ref document: 20020627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020822

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020822

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021128

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATMED AG

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030225

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20030612

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20031119

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040531

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20080502

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20080514

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20081128

Year of fee payment: 17

BERE Be: lapsed

Owner name: *HERSHKOVIZ RAMI

Effective date: 20090531

Owner name: *LIDER OFER

Effective date: 20090531

Owner name: *COHEN IRUN R

Effective date: 20090531

Owner name: *YEDA RESEARCH AND DEVELOPMENT CO. LTD

Effective date: 20090531

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090531

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090531

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20100525

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20100430

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100505

Year of fee payment: 19

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110501

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120131

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69232615

Country of ref document: DE

Effective date: 20111201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111201